1932

Abstract

Myelodysplastic syndromes (MDS) represent a collection of stem cell disorders characterized by impaired hematopoiesis resulting in low peripheral blood counts. The majority of patients with MDS present with symptoms related to anemia; however, bleeding and infection are the most common causes of death. The median age of diagnosis is 72 and the median survival is 2.5 years. Lenalidomide, azacitidine, and decitabine are all FDA-approved agents to treat MDS; however, the only potential cure for MDS remains stem cell transplantation.

Loading

Article metrics loading...

/content/journals/10.1146/annurev.med.051308.132852
2010-02-18
2024-12-13
Loading full text...

Full text loading...

/content/journals/10.1146/annurev.med.051308.132852
Loading
/content/journals/10.1146/annurev.med.051308.132852
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error